Chemokine CXCL14; a double-edged sword in cancer development.

Arezoo Gowhari Shabgah, Zahraa Haleem Al-Qaim, Alexander Markov, Alexei Valerievich Yumashev, Fatemeh Ezzatifar, Majid Ahmadi, Seyed Mohammad Gheibihayat, Jamshid Gholizadeh Navashenaq

International immunopharmacology 2021 Aug

filter terms:

Cancer is a leading cause of death worldwide and imposes a substantial financial burden. Therefore, it is essential to develop cost-effective approaches to inhibit tumor growth and development. The imbalance of cytokines and chemokines play an important role among different mechanisms involved in cancer development. One of the strongly conserved chemokines that is constitutively expressed in skin epithelia is the chemokine CXCL14. As a member of the CXC subfamily of chemokines, CXCL14 is responsible for the infiltration of immune cells, maturation of dendritic cells, upregulation of major histocompatibility complex (MHC)-I expression, and cell mobilization. Moreover, dysregulation of CXCL14 in several cancers has been identified by several studies. Depending on the type or origin of the tumor and components of the tumor microenvironment, CXCL14 plays a conflicting role in cancer. Although fibroblast-derived CXCL14 has a tumor-supportive role, epithelial-derived CXCL14 mainly inhibits tumor progression. Hence, this review will elucidate what is known on the mechanisms of CXCL14 and its therapeutic approaches in tumor treatment. CXCL14 is a promising approach for cancer immunotherapy. Copyright © 2021 Elsevier B.V. All rights reserved.

Citation

Arezoo Gowhari Shabgah, Zahraa Haleem Al-Qaim, Alexander Markov, Alexei Valerievich Yumashev, Fatemeh Ezzatifar, Majid Ahmadi, Seyed Mohammad Gheibihayat, Jamshid Gholizadeh Navashenaq. Chemokine CXCL14; a double-edged sword in cancer development. International immunopharmacology. 2021 Aug;97:107681